Skip to main content
Premium Trial:

Request an Annual Quote

PacBio, VisiGen, Helicos Offer Progress Updates


This year started off with a bang for the next-gen sequencing community. At two February conferences — Advances in Genome Biology and Technology in Marco Island, Fla., and the Association of Biomolecular Resource Facilities annual meeting in Salt Lake City — representatives from a number of the next line of next-gen vendors gave status reports on their platforms.

It can safely be said that the most anticipated came from Pacific Biosciences, which emerged from stealth mode with results from its prototype instrument. Known as SMRT sequencing (that's "single molecule, real-time"), the technology is currently running at 10 bases per second, and tests with circularized templates have routinely generated reads of 1,500 bases or more. The company has a staff of 100 and expects to double in size this year, says CEO Hugh Martin — he'll also be looking to raise about $80 million in funding to cover commercialization costs. Martin says PacBio expects to be selling instruments to early adopters in 2010, and that its price is targeted to be in the same range as ABI's SOLiD or Illumina's next-gen sequencer. CTO Steve Turner says the instrument has successfully worked with linear and circular, as well as single- and double-stranded, DNA.

Susan Hardin presented VisiGen's sequencer at ABRF. Like PacBio's technology, VisiGen monitors a polymerase in real time as it incorporates bases to a DNA strand to read the sequence. The platform is still in early stages, but she said her initial target was to generate 1 megabase of sequence per second per instrument, and that the company would be offering a sequencing service by the end of 2009. She also said that the company was awarded its first patent.

Helicos, meanwhile, announced its first instrument order — to genomic services provider Expression Analysis in Durham, NC — and also presented results of a canine BAC that the company had sequenced. The single-molecule platform uses a melt-and-resequence strategy to cover each base twice, said Bill Efcavitch, senior vice president of product R&D. "One of the advantages of single-molecule sequencing is that the error rate stays flat," he added.

Also at AGBT, a team from Danaher Motion ushered attendees in to introduce them to the Polonator, the open-platform sequencer commercialized from George Church's lab with a price tag of $150,000.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.